Business Context and Reporting Period
Company: Materialise NV
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Second Quarter and Half-Year ended June 30, 2026
Filing Date: August 27, 2026
Business Overview: Materialise provides software solutions and 3D printing services across healthcare, automotive, aerospace, and consumer goods sectors. The company operates through three segments: Materialise Medical, Materialise Software, and Materialise Manufacturing.
Key Financial Metrics
Second Quarter 2026 (vs. Q2 2025)
- Total Revenue: 70,073 kEUR (Increase of 8.1%)
- Gross Profit: 39,776 kEUR (Margin: 56.8%, down from 58.3%)
- Operating Profit: 2,785 kEUR (Stable vs. 2,730 kEUR)
- Net Profit: 3,331 kEUR (Sharp increase from 199 kEUR)
- Adjusted EBITDA: 9,593 kEUR (Increase of 15.7%)
- Free Cash Flow: 5,625 kEUR (vs. negative operating cash flow of 27 kEUR in prior year)
Half-Year 2026 (vs. H1 2025)
- Total Revenue: 136,349 kEUR (Increase of 3.9%)
- Gross Profit: 77,670 kEUR (Margin: 57.0%, up from 56.8%)
- Operating Profit: 4,875 kEUR (Increase from 3,303 kEUR)
- Net Profit: 5,152 kEUR (Turnaround from net loss of 337 kEUR)
- Adjusted EBITDA: 17,642 kEUR (Increase of 22.2%)
- Free Cash Flow: 11,368 kEUR
Liquidity and Balance Sheet (as of June 30, 2026)
- Cash and Cash Equivalents: 133,735 kEUR
- Gross Debt: 59,521 kEUR (Decreased from 63,113 kEUR at year-end 2025)
- Net Cash Position: 74,214 kEUR
- Share Buybacks: 1,070,797 shares repurchased for 5,212 kEUR
Material Changes vs. Prior Period
- Segment Performance:
- Medical: Revenue grew 12.2% (Q2) and 9.6% (H1). Adjusted EBITDA margins remained strong at 31.3% (Q2) and 29.7% (H1).
- Software: Revenue declined 2.7% (Q2) and 2.1% (H1). Adjusted EBITDA margins compressed to 10.2% (Q2) and 10.9% (H1).
- Manufacturing: Revenue grew 6.7% (Q2) but declined 1.2% (H1). The segment significantly improved profitability, moving from negative Adjusted EBITDA of (807) kEUR in Q2 2025 to (285) kEUR in Q2 2026, and nearly breakeven at (4) kEUR for H1 2026.
- Financial Results: Net profit surged due to a significant improvement in net financial results (242 kEUR income in Q2 2026 vs. 3,052 kEUR expense in Q2 2025), driven by favorable foreign exchange conditions compared to the prior year.
- Operating Expenses: R&D expenses increased 7.4% in H1 2026 due to investments in Medical and Software segments. S&M and G&A expenses remained stable.
Guidance, Outlook, and Risks
- Unusual Items: Q2 2026 operating income included non-recurring charges of 689 kEUR related to the impairment of tangible and intangible assets from the transfer of the eyewear business. Divestiture-related expenses totaled 169 kEUR.
- Non-IFRS Measures: Management utilizes Adjusted EBIT and Adjusted EBITDA to monitor performance, excluding share-based compensation, restructuring costs, and impairments. These measures do not reflect cash requirements for debt service or capital asset costs.
- Shareholder Returns: The company continued its share buy-back program, reducing the share count and increasing net shareholders' equity to 256,268 kEUR.
- Risks: The filing notes that non-IFRS measures may not be comparable to other companies and do not account for future unusual items. Foreign exchange fluctuations significantly impacted financial results in the prior year, though conditions improved in 2026.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 12.2% growth in the Medical segment versus the decline in the Software segment.
- Manufacturing Turnaround: Confirm the drivers behind the Manufacturing segment's move toward breakeven Adjusted EBITDA and whether this trend is sustainable.
- FX Impact: Assess the extent to which the sharp increase in net profit is driven by favorable foreign exchange results versus core operational improvements.
- Divestiture Costs: Review the final impact of the eyewear and RapidFit divestitures on future impairment charges and one-time costs.
- Cash Flow Consistency: Validate the strong free cash flow generation (11,368 kEUR for H1) against capital expenditure plans and debt repayment schedules.